← All trials
NCT06250504
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 27, 2024
- Primary completion
- Jul 31, 2025
- Completion date
- Mar 31, 2026
- First posted
- Feb 9, 2024
- Last posted
- Apr 17, 2024
- Enrollment
- 2000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Africa Health Research InstituteLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.